$NuScale Power(SMR)$ secures a $25B agreement with ENTRA1 Energy, a strong validation of its capability. While market attention was elsewhere, informed choices had spoken volumes. SMR is on a steady path, and its progress is worth watching.
$Palantir Technologies Inc.(PLTR)$ is on another surge! The stock broke through the 20-day moving average strongly—even more stable than NVIDIA lately. No need to gamble, just trust it.
$Direxion Daily S&P Biotech Bull 3x Shares(LABU)$ NAILED the biotech bounce with LABU! With FDA approvals speeding up and M&A heating up, taking some profits but keeping a moonbag - this sector's just getting started!
$Alibaba(BABA)$ is still solid—this rebound confirms my thesis. With strong fundamentals and dual focus on AI and e-commerce, I'm holding steady and waiting for value to shine through.
$Intel(INTC)$ Made a small profit, finally saw my years of technical analysis pay off. That moment of validation during the review? Totally worth it. The market may lie, but the charts never do.
$CTIHK(06055)$ It may not be flashy or headline-grabbing, but its roots run deep and its purpose is clear. This isn't a show pony，it’s a steady climber destined for a seat of power. With its pedigree and mandate, nothing else really needs to shine.
$Tencent Music(TME)$ Lately I’ve been feeling that music is not just for fun anymore，it’s moving into real healthcare. Tencent Music is killing it. With over 40 million licensed tracks and solid social + live-streaming features, it’s way more than just a music app. Now they’re even trying AI music therapy like healing through tunes, how wild is that? Ma Huateng’s reputation is solid, no big scandals, and their business keeps growing. By 2025, both revenue and profits are expected to keep climbing, and margins are improving too. Honestly, a company that lets people sing and make money? I’m holding tight.
$CARSGEN-B(02171)$ is accelerating its focus on off-the-shelf CAR-T cell therapy, with a subsidiary valued at an impressive 1 billion RMB. The company’s first commercialized product, Zevorcabtagene Autoleucel, has generated 39.4 million RMB in sales, and an application for the world’s first CAR-T therapy targeting solid tumors is set to be submitted in the first half of the year. This marks a crucial milestone for the company and could be a game-changer in the industry. Investors should keep a close eye on CARsgen’s R&D progress—its innovations hold great promise!
$BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS(ONC)$'s rise in the biotech industry is truly remarkable! It's projected that by 2025, the company will achieve positive GAAP operating profit, marking a milestone event that will elevate its standing in the industry. What's even more impressive is that BeiGene's market cap has surpassed that of Heng Rui Medicine for the first time, showcasing its growing market dominance. Its core product, Bruton’s tyrosine kinase (BTK) inhibitor Zanubrutinib, has seen strong performance, with sales reaching 12.9 billion RMB in the first three quarters of 2024, a 91% year-on-year growth. Additionally, the approval of Tislelizumab for gastric cancer in the U.S. has helped push its overseas revenue above 50%. With such stro
$H World Group(HTHT)$ During the National Day holiday in 2024, I stayed at Huazhu's All Seasons Hotel while traveling, and the experience was pretty good—definitely worth it. The profits from their stock have already covered the cost of my stay! Chain hotels like this are a "slow business," but also a sustainable one for the long term.